Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
NuGen Medical Devices Inc ( (TSE:NGMD) ) has shared an update.
NuGen Medical Devices Inc. has announced that its EziAutoJector® product line has been approved for inclusion in the NHS Drug Tariff in the UK. This approval allows individuals with diabetes to receive the needle-free insulin delivery device at no cost as part of NHS-funded care, aligning with NICE guidelines for personalized patient choice. The approval is expected to enhance NuGen’s market positioning by increasing product accessibility and reducing environmental impact through decreased biohazardous waste, supporting NHS environmental and cost-efficiency goals.
More about NuGen Medical Devices Inc
NuGen Medical Devices Inc. is a leader in needle-free subcutaneous drug-delivery technology. The company develops next-generation needle-free devices, with its flagship InsuJet™ system approved in 42 countries, aiming to improve the lives of millions of people with diabetes worldwide.
Average Trading Volume: 122,878
Technical Sentiment Signal: Sell
Current Market Cap: C$10.22M
For an in-depth examination of NGMD stock, go to TipRanks’ Overview page.